Evoke Pharma (EVOK) shares surged more than 130% pre-bell Monday after the company reported results from a real-world study showing significant statistical improvement for its diabetic gastroparesis nasal therapy over oral metoclopramide.
Monte Rosa Therapeutics (GLUE) shares advanced 42% after the company said it secured a global license deal with Novartis (NVS) to advance therapies for multiple immune-mediated conditions.
Revance Therapeutics (RVNC) shares rose 22%, rebounding from Friday's slide.
Focus Impact Acquisition (FIAC) shares were up 15%, adding to Friday's gains.
MEI Pharma (MEIP) shares increased 12% following a muted session.
Price: 11.75, Change: +6.62, Percent Change: +129.04
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。